After a Dense-Breast Notification: What the DENSE Trial Actually Showed

A dense-breast notification is a fact about your mammogram, not a diagnosis or a prescription. Since September 2024, every mammography report in the United States carries standardized language about breast density, and for many women the letter raises a question it does not answer: should I do something more? The clearest randomized evidence on that question comes from the DENSE trial, published in the New England Journal of Medicine in 2019. In women with extremely dense breasts and a normal mammogram, adding a screening MRI roughly halved the rate of cancers that surface between screening rounds, while also generating more recalls, more false alarms, and more benign biopsies.

What the notification actually says

The Food and Drug Administration amended the Mammography Quality Standards Act in a final rule issued March 10, 2023, with enforcement beginning September 10, 2024. Facilities must now give every patient one of two standardized statements. Women with dense tissue are told that dense breasts can hide cancers on a mammogram and that other imaging tests may help find them, and are directed to discuss their individual situation with a healthcare provider.

Two points are easy to miss. The notification describes a population-level fact about how dense tissue behaves on imaging; it does not say that any individual has an above-average personal risk that demands action. And the rule mandates disclosure, not a recommendation. It does not tell facilities to order more tests, and it is neither an endorsement of supplemental screening nor a safety all-clear. Reading the letter as an instruction rather than as information is the most common misinterpretation.

What the DENSE trial tested

DENSE was a multicenter randomized controlled trial in the Netherlands that enrolled 40,373 women aged 50 to 75 with extremely dense breast tissue and a normal screening mammogram. Participants were assigned in a 1-to-4 ratio to be invited for supplemental MRI or to continue with mammography alone. The primary outcome was the difference in interval cancers, meaning cancers diagnosed in the two years between routine mammograms. Interval cancers matter because they tend to be found because of symptoms rather than screening, and they are, on average, more aggressive than screen-detected tumors.

Randomizing tens of thousands of women to answer a screening question is unusual and valuable. Most claims about supplemental imaging rest on cancer-detection counts alone, which reward any test that finds more spots without accounting for the cost of chasing them. By fixing on interval cancers, DENSE asked the harder and more honest question of whether the extra imaging changes what the mammogram misses.

What it found

The interval-cancer rate was 2.5 per 1000 screenings in the group invited for MRI and 5.0 per 1000 in the mammography-only group, a difference of 2.5 per 1000 (95% confidence interval 1.0 to 3.7). In relative terms that is roughly a halving. The absolute gap is smaller than the relative figure sounds, which is the usual pattern when a baseline event is already uncommon.

The benefit tracked closely with whether women actually used the MRI. Only 59 percent of those invited accepted. Among women who underwent the scan, the interval-cancer rate fell to 0.8 per 1000; among those who declined, it was 4.9 per 1000, essentially the same as controls. The MRI detected cancer in 16.5 per 1000 women who were screened, so it was genuinely finding tumors the mammogram had not.

Those findings came with a cost that the notification's phrase "other imaging tests may help" does not convey. The false-positive rate was 79.8 per 1000 screenings. Of women recalled for additional testing after MRI, only 17.4 percent turned out to have cancer, and of those sent for biopsy, only 26.3 percent did. In plain terms, most women flagged by the first-round MRI did not have cancer, and many underwent further imaging or a biopsy to establish that. Serious adverse events during or right after the scan were rare, at about 0.1 percent.

Weighing benefit against harm

DENSE is a benefit-and-harm ledger, not a green light. On the benefit side sit fewer interval cancers and a plausible route to catching aggressive tumors earlier. On the harm side sit false positives, benign biopsies, the anxiety of a recall, the contrast injection an MRI requires, and cost. The trial reported first-round results over a two-year window; whether halving interval cancers translates into fewer breast-cancer deaths is a longer question that a single screening-round endpoint cannot settle, and later DENSE rounds showed the detection yield falls after the first scan once the backlog of hidden cancers is cleared.

The population also matters. DENSE studied women with extremely dense breasts, category D, the roughly ten percent with the densest tissue, not the far larger group with heterogeneously dense category C breasts who also receive the notification. The trial does not directly speak to that larger group, and it does not compare MRI against ultrasound or newer tomosynthesis. Extending its result to every woman who gets a density letter stretches the evidence past what was tested.

This article is educational and is not medical advice. Whether supplemental screening makes sense for a given person depends on personal risk, values about false positives, and access, and it is a decision to make with a clinician who knows the full history rather than one the notification settles on its own.

The reviewer's bottom line

DENSE did what good randomized evidence should: it quantified both sides. Supplemental MRI in extremely dense breasts reduced interval cancers by roughly half and, in the same breath, produced a substantial run of false positives and benign biopsies. The FDA notification is a prompt to have that conversation, informed by numbers like these, not a verdict on it.